Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EZH2 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1
EZH2 mutation	Acute Myelogenous Leukemia	EZH2 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	tazemetostat Sensitive: C1 - Off-label tazemetostat Sensitive : C1	tazemetostat Sensitive: C1 - Off-label tazemetostat Sensitive : C1
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	valemetostat Sensitive: C2 – Inclusion Criteria valemetostat Sensitive : C2	valemetostat Sensitive: C2 – Inclusion Criteria valemetostat Sensitive : C2
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3
EZH2 mutation	Myelodysplastic Syndrome	EZH2 mutation	Myelodysplastic Syndrome	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	CPI-169 + CPI-203 Sensitive: D – Preclinical CPI-169 + CPI-203 Sensitive : D	CPI-169 + CPI-203 Sensitive: D – Preclinical CPI-169 + CPI-203 Sensitive : D
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D
EZH2 mutation	Lymphoma	EZH2 mutation	Lymphoma	EED inhibitor Sensitive: D – Preclinical EED inhibitor Sensitive : D	EED inhibitor Sensitive: D – Preclinical EED inhibitor Sensitive : D
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	SHR-2554 Sensitive: D – Preclinical SHR-2554 Sensitive : D	SHR-2554 Sensitive: D – Preclinical SHR-2554 Sensitive : D
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	chidamide + SHR-2554 Sensitive: D – Preclinical chidamide + SHR-2554 Sensitive : D	chidamide + SHR-2554 Sensitive: D – Preclinical chidamide + SHR-2554 Sensitive : D
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	USP47 inhibitor Sensitive: D – Preclinical USP47 inhibitor Sensitive : D	USP47 inhibitor Sensitive: D – Preclinical USP47 inhibitor Sensitive : D